Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Raderer

Showing results (141-150 of 172) with videos related to

Pageof 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2000
Value of peptide receptor scintigraphy using (123)I-vasoactive intestinal peptide and (111)In-DTPA-D-Phe1-octreotide in 194 carcinoid patients: Vienna University Experience, 1993 to 1998M Raderer, A Kurtaran, M Leimer, et al.
Gut|February 15, 2011
EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALTA Ruskoné-Fourmestraux, W Fischbach, B M P Aleman, et al.
British Journal of Cancer|September 1, 1999
Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinomaW Scheithauer, G V Kornek, M Raderer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 7, 2008
Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patientsJ Valencak, F Weihsengruber, K Rappersberger, et al.
Liver|February 13, 2001
18F-fluorodeoxyglucose (FDG)-PET features of focal nodular hyperplasia (FNH) of the liverA Kurtaran, A Becherer, F Pfeffel, et al.
Cancer|June 22, 2000
A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinomaH Ulrich-Pur, G V Kornek, M Raderer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2022
Corrigendum to "Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up": [Annals of Oncology 31 (2020) 17-29]E Zucca, L Arcaini, C Buske, et al.
The Journal of Clinical Endocrinology and Metabolism|May 6, 2004
Cytotoxic activity of camptothecin and paclitaxel in newly established continuous human medullary thyroid carcinoma cell linesK Kaczirek, M Schindl, A Weinhäusel, et al.
British Journal of Cancer|February 23, 1999
Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo resultsM Raderer, G Hamilton, A Kurtaran, et al.
Oncology|April 15, 1999
Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancerM Raderer, M H Hejna, J B Valencak, et al.
Pageof 18

Showing results (141-150 of 172) with videos related to

Sort By:
Pageof 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2000
Value of peptide receptor scintigraphy using (123)I-vasoactive intestinal peptide and (111)In-DTPA-D-Phe1-octreotide in 194 carcinoid patients: Vienna University Experience, 1993 to 1998M Raderer, A Kurtaran, M Leimer, et al.
Gut|February 15, 2011
EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALTA Ruskoné-Fourmestraux, W Fischbach, B M P Aleman, et al.
British Journal of Cancer|September 1, 1999
Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinomaW Scheithauer, G V Kornek, M Raderer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 7, 2008
Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patientsJ Valencak, F Weihsengruber, K Rappersberger, et al.
Liver|February 13, 2001
18F-fluorodeoxyglucose (FDG)-PET features of focal nodular hyperplasia (FNH) of the liverA Kurtaran, A Becherer, F Pfeffel, et al.
Cancer|June 22, 2000
A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinomaH Ulrich-Pur, G V Kornek, M Raderer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2022
Corrigendum to "Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up": [Annals of Oncology 31 (2020) 17-29]E Zucca, L Arcaini, C Buske, et al.
The Journal of Clinical Endocrinology and Metabolism|May 6, 2004
Cytotoxic activity of camptothecin and paclitaxel in newly established continuous human medullary thyroid carcinoma cell linesK Kaczirek, M Schindl, A Weinhäusel, et al.
British Journal of Cancer|February 23, 1999
Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo resultsM Raderer, G Hamilton, A Kurtaran, et al.
Oncology|April 15, 1999
Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancerM Raderer, M H Hejna, J B Valencak, et al.
Pageof 18